Stereospecific recognition of S-fluoxetine enabled by HOF-101-based multimodal probe

Area of Science:

• Materials Science
• Analytical Chemistry
• Supramolecular Chemistry

Background:

• Chiral recognition of fluoxetine enantiomers is crucial due to differing pharmacological and toxicological profiles.
• Existing analytical methods require high selectivity for accurate enantiomer identification.
• Hydrogen-bonded organic framework-101 (HOF-101) offers potential for chiral recognition via its porous structure and hydrogen-bonding sites.

Purpose of the Study:

• To develop a multimodal chiral fluorescent probe for identifying fluoxetine enantiomers.
• To utilize HOF-101's properties for selective enantiomer recognition.
• To enhance medication safety and accuracy in chiral drug analysis.

Main Methods:

• Development of a multimodal probe using HOF-101.
• Application of colorimetric, fluorescent, and electrochemical detection methods.
• Investigation of enantiomer recognition mechanisms based on cavity confinement and hydrogen bonding.

Main Results:

• The probe achieved sub-nanomolar limits of detection (0.464 nM fluorescence, 0.0303 nM electrochemistry).
• Selective recognition of S-fluoxetine via competitive hydrogen bonding and cavity interaction, causing structural collapse and signal changes.
• R-fluoxetine was excluded due to steric hindrance, resulting in minimal signal alteration.

Conclusions:

• The multimodal probe offers a new technical solution for rapid and sensitive chiral drug recognition.
• Cross-validation across detection modes confirms reproducibility and eliminates artifacts.
• This approach enhances accuracy in analyzing chiral pharmaceuticals.